Aquestive Therapeutics earnings were -$65.0M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest AQST earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$13.5M, down 40.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AQST reported annual earnings of -$44.1M, with 460.8% growth.
Aquestive Therapeutics Earnings Reports & History FAQ
What were Aquestive Therapeutics's earnings last quarter?
On AQST's earnings call on Invalid Date, Aquestive Therapeutics (NASDAQ: AQST) reported Q2 2025 earnings per share (EPS) of -$0.14, up 366.67% year over year. Total AQST earnings for the quarter were -$13.55 million. In the same quarter last year, Aquestive Therapeutics's earnings per share (EPS) was -$0.03.
Is Aquestive Therapeutics profitable or losing money?
As of the last Aquestive Therapeutics earnings report, Aquestive Therapeutics is currently losing money. Aquestive Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$65.04 million, a 152.89% increase year over year.
What was AQST's earnings growth in the past year?
As of Aquestive Therapeutics's earnings date in Invalid Date, Aquestive Therapeutics's earnings has grown year over year. AQST earnings in the past year totalled -$65.04 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.